Non-Albuterol Based Short-Acting Beta Agonists for Asthma Management

Available Non-Albuterol SABAs

The American Academy of Allergy, Asthma, and Immunology recommends levalbuterol and pirbuterol as equivalent alternatives to albuterol for acute symptom relief in asthma, providing equivalent bronchodilation 1, 2, 3
Levalbuterol is the R-enantiomer of albuterol and has an effectiveness and side effect profile indistinguishable from racemic albuterol 2, 3
Pirbuterol is listed as one of the three most commonly used SABAs in the United States alongside albuterol and levalbuterol 1, 2, 3

All SABAs—albuterol, levalbuterol, and pirbuterol—provide equivalent bronchodilation with similar safety profiles when used at recommended doses, according to the American Academy of Family Physicians 1, 2, 3
Onset of action is ≤5 minutes for all SABAs 2, 3
Peak effect is 30-60 minutes for all SABAs 2, 3
Duration is 4-6 hours for all SABAs 2, 3

Ipratropium bromide can be used as an alternative bronchodilator for patients who cannot tolerate SABAs, as suggested by the Journal of Allergy and Clinical Immunology 1, 7
Ipratropium provides additive benefit when combined with SABAs in moderate-to-severe exacerbations in the ED setting 1, 7, 8

Oral short-acting beta-agonists are less potent, take longer to act, and have more side effects compared to inhaled formulations, and their use is strongly discouraged by the American Academy of Family Physicians 2, 3, 9
Increasing SABA use or using SABAs >2 days per week for symptom relief indicates inadequate asthma control and need for intensified anti-inflammatory therapy, according to the American Academy of Allergy, Asthma, and Immunology 1, 2, 3, 7